Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women

A. Crim, M. Rowland, Rachel Ruskin, J. Dvorak, M. Greenwade, A. Walter, J. Gillen, K. Ding, K. Moore, C. Gunderson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective Intraperitoneal (IP) chemotherapy (CT) for treatment of epithelial ovarian cancer (EOC) has been shown to provide a substantial OS advantage. This study aims to compare the toxicity and benefits of IP CT in patients ≥ 70 with those < 70. Methods We performed a single institution retrospective review of patients diagnosed with Stage IIA-IIIC EOC from 2000 to 2013 who received IP CT. Clinicopathologic characteristics were extracted, and survival was calculated. Results 133 patients were included with 100 pts. < 70 years old and 33 pts. ≥ 70 years old. Clinical trial enrollment was similar despite age. In trial enrolled patients, older patients received statistically fewer cycles of therapy (6.4 vs 5.8, p = 0.002) but had similar dose delays (0.9 vs 0.7, p = 0.72), and modifications (0.9 vs 0.36, p = 0.11). Median PFS (27 vs 31 months) and OS (71 and 62 months) were not statistically different. Grade 3/4 neutropenia was significantly worse in the older patients (82% vs 100%, p = 0.04). Neuropathy grade ≥ 2 and other non-hematologic toxicities were not different between age groups. Conclusions Despite completing fewer cycles of IP CT, older EOC patients had comparable survival to younger patients. The population of older patients receiving IP CT in this study were on clinical trial and likely to be heartier than the general older population. IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials.

Original languageEnglish (US)
Pages (from-to)268-272
Number of pages5
JournalGynecologic Oncology
Volume146
Issue number2
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Drug Therapy
Clinical Trials
Survival
Neutropenia
Population
Age Groups
Therapeutics
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. / Crim, A.; Rowland, M.; Ruskin, Rachel; Dvorak, J.; Greenwade, M.; Walter, A.; Gillen, J.; Ding, K.; Moore, K.; Gunderson, C.

In: Gynecologic Oncology, Vol. 146, No. 2, 01.08.2017, p. 268-272.

Research output: Contribution to journalArticle

Crim, A, Rowland, M, Ruskin, R, Dvorak, J, Greenwade, M, Walter, A, Gillen, J, Ding, K, Moore, K & Gunderson, C 2017, 'Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women', Gynecologic Oncology, vol. 146, no. 2, pp. 268-272. https://doi.org/10.1016/j.ygyno.2017.05.032
Crim, A. ; Rowland, M. ; Ruskin, Rachel ; Dvorak, J. ; Greenwade, M. ; Walter, A. ; Gillen, J. ; Ding, K. ; Moore, K. ; Gunderson, C. / Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 2. pp. 268-272.
@article{a8b08daa8737486eb1f5de82fda61583,
title = "Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women",
abstract = "Objective Intraperitoneal (IP) chemotherapy (CT) for treatment of epithelial ovarian cancer (EOC) has been shown to provide a substantial OS advantage. This study aims to compare the toxicity and benefits of IP CT in patients ≥ 70 with those < 70. Methods We performed a single institution retrospective review of patients diagnosed with Stage IIA-IIIC EOC from 2000 to 2013 who received IP CT. Clinicopathologic characteristics were extracted, and survival was calculated. Results 133 patients were included with 100 pts. < 70 years old and 33 pts. ≥ 70 years old. Clinical trial enrollment was similar despite age. In trial enrolled patients, older patients received statistically fewer cycles of therapy (6.4 vs 5.8, p = 0.002) but had similar dose delays (0.9 vs 0.7, p = 0.72), and modifications (0.9 vs 0.36, p = 0.11). Median PFS (27 vs 31 months) and OS (71 and 62 months) were not statistically different. Grade 3/4 neutropenia was significantly worse in the older patients (82{\%} vs 100{\%}, p = 0.04). Neuropathy grade ≥ 2 and other non-hematologic toxicities were not different between age groups. Conclusions Despite completing fewer cycles of IP CT, older EOC patients had comparable survival to younger patients. The population of older patients receiving IP CT in this study were on clinical trial and likely to be heartier than the general older population. IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials.",
author = "A. Crim and M. Rowland and Rachel Ruskin and J. Dvorak and M. Greenwade and A. Walter and J. Gillen and K. Ding and K. Moore and C. Gunderson",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2017.05.032",
language = "English (US)",
volume = "146",
pages = "268--272",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women

AU - Crim, A.

AU - Rowland, M.

AU - Ruskin, Rachel

AU - Dvorak, J.

AU - Greenwade, M.

AU - Walter, A.

AU - Gillen, J.

AU - Ding, K.

AU - Moore, K.

AU - Gunderson, C.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective Intraperitoneal (IP) chemotherapy (CT) for treatment of epithelial ovarian cancer (EOC) has been shown to provide a substantial OS advantage. This study aims to compare the toxicity and benefits of IP CT in patients ≥ 70 with those < 70. Methods We performed a single institution retrospective review of patients diagnosed with Stage IIA-IIIC EOC from 2000 to 2013 who received IP CT. Clinicopathologic characteristics were extracted, and survival was calculated. Results 133 patients were included with 100 pts. < 70 years old and 33 pts. ≥ 70 years old. Clinical trial enrollment was similar despite age. In trial enrolled patients, older patients received statistically fewer cycles of therapy (6.4 vs 5.8, p = 0.002) but had similar dose delays (0.9 vs 0.7, p = 0.72), and modifications (0.9 vs 0.36, p = 0.11). Median PFS (27 vs 31 months) and OS (71 and 62 months) were not statistically different. Grade 3/4 neutropenia was significantly worse in the older patients (82% vs 100%, p = 0.04). Neuropathy grade ≥ 2 and other non-hematologic toxicities were not different between age groups. Conclusions Despite completing fewer cycles of IP CT, older EOC patients had comparable survival to younger patients. The population of older patients receiving IP CT in this study were on clinical trial and likely to be heartier than the general older population. IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials.

AB - Objective Intraperitoneal (IP) chemotherapy (CT) for treatment of epithelial ovarian cancer (EOC) has been shown to provide a substantial OS advantage. This study aims to compare the toxicity and benefits of IP CT in patients ≥ 70 with those < 70. Methods We performed a single institution retrospective review of patients diagnosed with Stage IIA-IIIC EOC from 2000 to 2013 who received IP CT. Clinicopathologic characteristics were extracted, and survival was calculated. Results 133 patients were included with 100 pts. < 70 years old and 33 pts. ≥ 70 years old. Clinical trial enrollment was similar despite age. In trial enrolled patients, older patients received statistically fewer cycles of therapy (6.4 vs 5.8, p = 0.002) but had similar dose delays (0.9 vs 0.7, p = 0.72), and modifications (0.9 vs 0.36, p = 0.11). Median PFS (27 vs 31 months) and OS (71 and 62 months) were not statistically different. Grade 3/4 neutropenia was significantly worse in the older patients (82% vs 100%, p = 0.04). Neuropathy grade ≥ 2 and other non-hematologic toxicities were not different between age groups. Conclusions Despite completing fewer cycles of IP CT, older EOC patients had comparable survival to younger patients. The population of older patients receiving IP CT in this study were on clinical trial and likely to be heartier than the general older population. IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85020125922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020125922&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.05.032

DO - 10.1016/j.ygyno.2017.05.032

M3 - Article

VL - 146

SP - 268

EP - 272

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -